Over the last five years, the industry has traded as high as 20.80X, as low as 12.92X and at a median of 15.13X, as the chart ... Humira, are declining due to loss of exclusivity and biosimilar ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due ...

As you can see from the chart below, healthcare expenditures ... For example, Regeneron’s main drug Eylea faces biosimilar competition. It can use its $17.9 billion in cash (as of Q4 2024 ...

A similar search for PsA trials was planned and conducted, however the detailed article review did not identify any trial pairs to be eligible for these analyses based on the inclusion criteria ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

Opens in a new tab or window Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the ...

Sandoz pointed to the uptake of its Humira biosimilar Hyrimoz in the US through a private-label agreement with CVS biosimilar subsidiary Cordavis as one of the drivers of its biosimilar business ...

As a medication vital for improving patient outcomes, Humira's high cost presents employers with the challenge of balancing financial considerations with the opportunities offered by biosimilars ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Successful launches of biosimilars to HUMIRA and STELARA are key revenue drivers. Alvotech’s business-to-business model facilitates global reach, with one-third of revenues from ex-U.S. markets.